Mechanisms of Resistance to KRASG12C Inhibitors

Victoria Dunnett-kane, Pantelis Nicola, Fiona Blackhall, Colin Lindsay

Research output: Contribution to journalArticlepeer-review


KRAS is one of the most common human oncogenes, but concerted efforts to produce direct inhibitors have largely failed, earning KRAS the title of “undruggable”. Recent efforts to produce subtype specific inhibitors have been more successful, and several KRASG12C inhibitors have reached clinical trials, including adagrasib and sotorasib, which have shown early evidence of efficacy in patients. Lessons from other inhibitors of the RAS pathway suggest that the effect of these drugs will be limited in vivo by the development of drug resistance, and pre-clinical studies of G12C inhibitors have identified evidence of this. In this review we discuss the current evidence for G12C inhibitors, the mechanisms of resistance to G12C inhibitors and potential approaches to overcome them. We discuss possible targets of combination therapy, including SHP2, receptor tyrosine kinases, downstream effectors and PD1/PDL1, and review the ongoing clinical trials investigating these inhibitors.
Original languageEnglish
Pages (from-to)151
Issue number1
Publication statusPublished - 5 Jan 2021

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre


Dive into the research topics of 'Mechanisms of Resistance to KRASG12C Inhibitors'. Together they form a unique fingerprint.

Cite this